[Percutaneous cryoablation and (125)I seed implantation combined with chemotherapy for advanced pancreatic cancer: report of 67 cases].

• DOI: 10.3760/cma.j.issn.0253-3766.2012.12.013
• Publication Date: 2012-12-01
• Authors: Lizhi Niu; Lihua He; Liang Zhou; Zhenzhong Yang; Jiansheng Zuo; Kecheng Xu
• Keywords: Cryoablation; Concomitant

To assess the efficacy and safety of percutaneous cryoablation (PCC) (125)I seed implantation combined with chemotherapy for advanced pancreatic cancer.Sixty-seven patients cancer (6 in stage III, 61 IV) received PCC concomitant gemcitabine hydrochloride DDP chemotherapy. The clinical benefit response (CBR), survival rate therapy-related complications were assessed.All except one followed up over 1 year. 6-month 1-year rates 84.8% 33.4%, respectively. median progression free 6.3 months 5.5 group III IV (P > 0.05), respectively, while overall was 9.1 11.0 0.05). CR,PR SD achieved 5, 8, 54 patients, Fifty-four 50 67 experienced a ≥ 50% reduction pain score analgesic consumption, 18 2 kg weight gaining, KPS increasing from 71.2 ± 0.4 to (90.0 0.3, P < 80.6%. No serious fistula accompanied abdominal hemorrhage, bile leakage, acute pancreatitis needle track seeding 1, case, respectively.Percutaneous are effective safe treatment cancer.